<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The present study characterized the effects of TS-011 [N-(3-chloro-4-morpholin-4-yl) <z:chebi fb="1" ids="30396">phenyl</z:chebi>-N'-hydroxyimido <z:chebi fb="0" ids="16397">formamide</z:chebi>], a new selective inhibitor of the synthesis of <z:chebi fb="0" ids="34306">20-hydroxyeicosatetraenoic acid</z:chebi> (<z:chebi fb="0" ids="34306">20-HETE</z:chebi>), on the metabolism of <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> by human and rat renal microsomes and the inhibitory effects of this compound on hepatic <z:chebi fb="0" ids="38559">cytochrome P450</z:chebi> enzymes involved in drug metabolism </plain></SENT>
<SENT sid="1" pm="."><plain>The effects of TS-011 on the fall in cerebral blood flow following <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) and in reducing <z:mpath ids='MPATH_124'>infarct</z:mpath> size in <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> models were also examined since <z:chebi fb="0" ids="34306">20-HETE</z:chebi> may contribute to the development of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>TS-011 inhibited the synthesis of <z:chebi fb="0" ids="34306">20-HETE</z:chebi> by human renal microsomes and recombinant CYP4A11 and 4F2, 4F3A, and 4F3B enzymes with IC50 values around 10 to 50 nM </plain></SENT>
<SENT sid="3" pm="."><plain>It had no effect on the activities of CYP1A, 2C9, 2C19, 2D6, or 3A4 enzymes </plain></SENT>
<SENT sid="4" pm="."><plain>TS-011 inhibited the synthesis of <z:chebi fb="0" ids="34306">20-HETE</z:chebi> by rat renal microsomes with an IC50 of 9.19 nM, and it had no effect on epoxygenase activity at a concentration of 100 microM </plain></SENT>
<SENT sid="5" pm="."><plain>TS-011 (0.01-1 mg/kg i.v.) reversed the fall in cerebral blood flow and the increase in <z:chebi fb="0" ids="34306">20-HETE</z:chebi> levels in the cerebrospinal fluid of rats after SAH </plain></SENT>
<SENT sid="6" pm="."><plain>TS-011 also reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 35% following transient <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> and in <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> in rats </plain></SENT>
<SENT sid="7" pm="."><plain>Injection of <z:chebi fb="0" ids="34306">20-HETE</z:chebi> (8 or 12 mg/kg) into the carotid artery produced an <z:mpath ids='MPATH_124'>infarct</z:mpath> similar to that seen in the <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> model </plain></SENT>
<SENT sid="8" pm="."><plain>These studies indicate that blockade of the synthesis of <z:chebi fb="0" ids="34306">20-HETE</z:chebi> with TS-011 opposes <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> following SAH and reduces <z:mpath ids='MPATH_124'>infarct</z:mpath> size in ischemic models of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>